Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: Results of the gruppo Italiano per lo studio della sopravvivenza nell'infarto-1 study

Circulation

Volumn 98, Issue 24, 1998, Pages 2659-2665

  Franzosi, Maria Grazia ^a,f   Santoro, Eugenio ^a   De Vita, Claudio ^b   Geraci, Enrico ^c   Lotto, Antonio ^a   Maggioni, Aldo P ^a   Mauri, Francesco ^d   Rovelli, Fausto ^a   Santoro, Luigi ^a   Tavazzi, Luigi ^e   Tognoni, Gianni ^a  

^a GISSI Coordinating Centre   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^d A MANZONI HOSPITAL   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Myocardial infarction; Thrombolysis; Trials

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL;

EID: 0032534474     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.24.2659     Document Type: Article

References (29)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
2. Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, ed. Heart disease: A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia, Pa: WB Saunders Co; 1997:1215.
3. Gruppo Italiano per lo Studio della Streptochinasi nell'infarto miocardico (GISSI). Long-term effects of intravenous thrombolysis: final report of the GISSI study. Lancet. 1987;2:871-874.
4. ISAM (Intravenous Streptokinase in Acute Myocardial infarction) Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity and infarct size at 21 days. N Engl J Med. 1986;314:1465-1471.
5. The AIMS (APSAC Intervention Mortality Study) Trial Study Group. Effects of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1988;1:545-549.
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
7. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, for the ASSET (Anglo-Scandinavian Study of Early Thrombolysis) Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (ASSET). Lancet. 1988;2:525-530.
8. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet. 1993;342: 767-772.
9. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet. 1993;342:759-766.
10. Schröder R, Neuhaus K-L, Leizorovicz A, Linderer T, Tebbe U, for the ISAM Study Group. A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): long-term mortality and morbidity. J Am Coll Cardiol. 1987;9: 197-203.
11. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet. 1990;335:427-431.
12. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, for the Anglo-Scandinavian Study of Early Thrombolysis. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Lancet. 1990;335:1175-1178.
13. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
14. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: analysis and examples. Br J Cancer. 1977;35:1-39.
15. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
16. Van de Werf F. Thrombolysis for acute myocardial infarction: why is there no extra benefit after hospital discharge? Circulation. 1995;91: 2862-2864.
17. The Reperfusion Therapy Consensus Group. Selection of reperfusion therapy for individual patients with evolving myocardial infarction. Eur Heart J. 1997;18:1371-1381.
18. Simoons ML, Vos J, Tijssen JGP, Vermeer F, Verheugt FWA, Krauss XH, Manger Cats V. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5-year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol. 1989;14:1609-1615.
19. Cerqueira MD, Maynard C, Ritchie JL, Davis KB, Kennedy JW. Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction Trials. J Am Coll Cardiol. 1992;20: 1452-1459.
20. Hillis WS, Chamberlain DA, de Bono DP, Fox KAA, Murray RG, Julian DG, Pocock SJ, Wellwood M, Waters J, for the AIMS Study Group. Intravenous anistreplase in acute myocardial infarction: continued reduction in mortality up to 5 years: long-term results of the AIMS study. Eur Heart J. 1992;13:305. Abstract.
21. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R, for the ISIS Collaborative Group. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ. 1998;316: 1337-1343.
22. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, Rubison M, Tiefenbrunn AJ, Weaver WD, for the Participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation. 1994;90: 2103-2114.
23. European Secondary Prevention Study Group. Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet. 1996;347: 1203-1207.
24. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348:771-775.
25. Ross AM, Coyne KS, Moreyra E, Reiner JS, Greenhouse SW, Walker PL, Simoons ML, Draoui YC, Califf RM, Topol EJ, Van de Werf F, Lundergan CF, for the GUSTO-1 Angiographic Investigators. Extended mortality benefit of early postinfarction reperfusion. Circulation. 1998;97:1549-1556.
26. GISSI-Avoidable Delay Study Group. Epidemiology of avoidable delay in the care of patients with acute myocardial infarction in Italy: a GISSI-generated study. Arch Intern Med. 1995;155:1481-1488.
27. Califf RM, Newby LK. How much do we gain by reducing time to reperfusion therapy? Am J Cardiol. 1996;78(suppl 12A):8-15.
28. Herlitz J. The importance of reducing delay in acute myocardial infarction. Eur Heart J. 1996;17:338-340.
29. Tognoni G, Rovelli F. Italy: the health service as a laboratory. Lancet. 1996;348:169-170.